Hong Kong Pharmaceuticals and Healthcare Report Q1 2009
Business Monitor International, February 2009, Pages: 71
This Hong Kong Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Hong Kong's pharmaceuticals and healthcare industry.
According to BMI’s Asia Pacific Pharmaceuticals & Healthcare Business Environment Ranking table for Q109, Hong Kong’s pharmaceutical market remains viewed as the sixth-most attractive in the region, on a par with Taiwan. Over our five-year forecast period, BMI expects Hong Kong to be overtaken by countries like India, as they start to fulfil their potential. Nevertheless, due to its position as a gateway to mainland China and the traditional preference for branded products, Hong Kong should remain one of the large regional markets in Asia Pacific in value terms.
In October 2008, Hong Kong introduced a new strategic framework for the prevention and control of noncommunicable diseases. The framework was developed by the Department of Health (DoH), with input from experts of various disciplines and making reference to the World Health Organization (WHO)’s guiding principles in disease prevention and health promotion. Non-communicable diseases have grown rapidly in recent years, leading to shortened life expectancy and affecting quality of life in the territory.
With an ageing population, the impact of non-communicable diseases in Hong Kong is anticipated to grow further in the decades ahead. By 2031, the portion of people older than 65 is expected to top 24% of the total population in Hong Kong, up from around 12% at present. The figures also indicate a sizeable opportunity for drugmakers active in the prescription and patented segments in particular. The government is also planning to set up new medical centres of excellence, which will house specialist units dealing with therapeutic areas of importance, specifically paediatrics and neuroscience.
Illustrating the growing potential of the regional pharmaceutical market, Hong Kong-based Cathay Pacific Airways launched a new cold chain cargo service in September 2008. Pharma Lift has four components and allows a variety of medicines to be transported at the correct temperature. BMI believes that the service offered by Cathay Pacific is unparalleled in the airfreight sector and expects conscientious drugmakers to utilise it frequently. Pharma Lift is a full spectrum cold chain package, using dry ice for transporting frozen or chilled items, as well as various electrical heaters for medicines that need to be stored at room temperature.
In the meantime, growing headwinds from the global economic slowdown and ongoing financial market volatility will further hamper the territory's annual GDP growth. We have lowered our estimate for real GDP growth in 2008 to 4.6% (from 5.0% previously) and have also revised down our forecast for 2009, to 4.1% (from 4.8%), which should have an impact on the pharmaceutical values in the short term. Hong Kong's domestic demand continues to suffer from high inflation and ongoing financial market turmoil, which has somewhat eroded wealth and consumer confidence, although private consumption remained the largest single contributor to the overall growth rate.
Executive Summary
Hong Kong Pharmaceuticals And Healthcare Industry SWOT
Hong Kong Political SWOT
Hong Kong Economic SWOT
Hong Kong Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q109
Limits Of Potential Returns
Risks To Realisation Of Returns
Hong Kong – Market Summary
Regulatory Regime
Intellectual Property Issues
Counterfeit Drugs
Pricing And Reimbursement Developments
Industry Trends And Developments
Epidemiology
Healthcare Sector
Table: Secondary/Tertiary Public Sector Health Services In Hong Kong
Healthcare Sector Reforms
Healthcare Financing
Hospital Pharmacy Sector
Public Procurement Of Medicines
Pharmaceutical Industry
Traditional Chinese Medicines
Foreign Industry Developments
Supply Chain
Research And Development
Medical Devices
Table: Examples Of Medical Devices
Overall Market Forecast
Table: Hong Kong – Drug Expenditure Indicators, 2003-2013
Key Growth Factors – Industry
Table: Hong Kong – Health Expenditure Indicators, 2003-2013
Key Growth Factors – Macroeconomic
Table: Hong Kong – Economic Activity
Prescription Market Forecast
Table: Hong Kong – Prescription Market Indicators, 2003-2013 (HKDmn unless otherwise stated)
Patented Drug Market Forecast
Table: Hong Kong – Patented Market Indicators, 2003-2013
Generic Drug Market Forecasts
Table: Hong Kong – Generic Market Indicators, 2003-2013
OTC Market Forecast
Table: Hong Kong – OTC Market Indicators, 2003-2013 (HKDmn unless otherwise stated)
Export/Import Forecasts
Table: Hong Kong – Pharmaceuticals Export/Import Indicators, 2003-2013 (US$mn)
Other Healthcare Data And Forecasts
Table: Hong Kong – Other Healthcare Indicators
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Table: Hong Kong’s Leading Drugmakers And Products, Q406
Company Profiles
Leading Multinational Companies
GlaxoSmithKline
Pfizer
Sanofi-Aventis
Merck & Co
Novartis
Local Pharmaceutical Companies
Wuyi International Pharmaceutical
CK Life Sciences
South Asia Pharmamedic Ltd
C&Y Pharmaceutical Investment Holding
Vida Laboratories
Country Snapshot: Hong Kong Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2005-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
- GlaxoSmithKline
- Pfizer
- Sanofi-Aventis
- Merck & Co
- Novartis
- Wuyi International Pharmaceutical
- CK Life Sciences
- South Asia Pharmamedic Ltd
- C&Y Pharmaceutical Investment Holding
- Vida Laboratories
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
